Affidea Group Partners with Reset Health
Affidea is thrilled to unveil the Roczen platform in collaboration with Reset Health, aimed at revolutionizing the management of obesity and type 2 diabetes. This innovative partnership promises to enhance personalized care through the integration of GLP-1 medications and focus on achieving improved health outcomes for patients across its facilities.
Introducing the Roczen Platform
This new solution will be rolled out across various Affidea locations, giving patients access to a clinically validated, data-driven care pathway. This pathway merges advanced analytics with evidence-based interventions, ensuring effective management of obesity and its chronic conditions.
Digital and Doctor-Led Services
The Roczen platform is designed to provide a fully digital, doctor-led service that encourages sustainable lifestyle changes alongside innovative medical interventions to combat obesity and type 2 diabetes.
Key Features of the Roczen Platform
Among the standout features of this solution are:
- A comprehensive pathway supporting patient engagement and success.
- Continuous tracking of vital health metrics for timely interventions.
- Personalization of treatment plans based on real-time patient data.
- Direct communication between patients and healthcare providers, enhancing ongoing support.
- Guidance on sustainable changes, including nutrition and physical activity.
- Access to GLP-1 medications for eligible patients, aiding in chronic disease management.
Expanding Clinical Services
The collaboration with Reset Health and the launch of the Roczen platform signify a crucial advancement in Affidea's clinical offerings. This initiative responds to the increasing need for efficient and effective weight management and diabetes care. This partnership is in line with Affidea's commitment to providing innovative, patient-centered care pathways, which ensure that individuals have access to modern therapeutic options. By fusing digital therapeutics with professional health support, Affidea's facilities will deliver personalized, affordable care aimed at enhancing the management of obesity and type 2 diabetes. This approach also mitigates long-term health complications associated with these conditions.
Comments from Leadership
Dr. Charles Niehaus, Executive Director for Affidea Group, expressed his enthusiasm: "At Affidea, we focus on delivering the highest quality of care tailored to our patients’ individual needs. The Roczen platform allows us to provide a clinically validated method for managing weight and diabetes, addressing two of today's most urgent health challenges. By offering evidence-based interventions, we empower our patients to enhance their health and improve their quality of life."
Dr. David Wong, Chairman at Reset Health, added: "We are thrilled to collaborate with Affidea, leading the way in offering high-quality, clinically-proven weight and diabetes care throughout the continent. Through Roczen, we provide individualized care that meets the unique needs of each patient, ultimately aiming for better health outcomes and improved patient satisfaction."
Understanding Obesity and Its Implications
As highlighted by multiple health reports, obesity poses significant risks, leading to a concerning rise in related health conditions. Key statistics underscore the need for proactive management and intervention:
- Nearly 60% of adults are classified as overweight, with 23% categorized as obese.
- An estimated 1.2 million deaths annually in Europe relate to overweight and obesity.
- By 2030, obesity rates might increase by 10-15%, potentially affecting 30% of the adult population.
- A strong relationship exists between obesity and type 2 diabetes, with a significant percentage of individuals with diabetes being overweight.
- Obesity also correlates with an increased risk of various health issues, including obstructive sleep apnea and osteoarthritis.
- Mental health impacts are also significant, linking obesity with heightened risks of depression and anxiety.
About Affidea Group
Affidea is a premier provider of community-based polyclinics, advanced diagnostics, and specialized services throughout Europe. With a history dating back to 1991, the company operates numerous centers that cater to the healthcare needs of millions annually. Its outstanding commitment to patient safety has earned Affidea numerous accolades, establishing it as a recognized leader in diagnostic imaging.
About Reset Health
Reset Health is at the forefront of digital health solutions, focusing on personalized lifestyle interventions through its innovative Roczen platform. The company collaborates with various entities to enhance health outcomes for people dealing with obesity and other related disorders. Reset Health's operations span various health environments, delivering valuable support to countless patients globally.
Frequently Asked Questions
What is the Roczen platform?
The Roczen platform is a digital solution developed by Reset Health for managing obesity and type 2 diabetes with personalized care plans.
How does Affidea aim to improve patient healthcare?
Affidea focuses on integrating innovative digital solutions with professional healthcare support to provide personalized, effective care.
What are GLP-1 medications?
GLP-1 medications are a class of drugs that help in weight control and diabetes management by regulating appetite and insulin secretion.
Why is obesity considered a major health concern?
Obesity is linked to numerous health problems, including diabetes, heart disease, and mental health challenges, making its management essential.
How will the partnership impact patients?
The partnership aims to offer patients access to advanced treatment pathways, enhancing their engagement and health outcomes in managing obesity and diabetes.
